Gane E. Safety and Efficacy at 1 year after Switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use. PS-156.
Veiligheid en immunogeniciteit van ChAdOx1-vaccin tegen riftvalleykoorts
okt 2023 | Vaccinatie, Virale infecties